Semaglutide denied due to quantity / dose limits by Cigna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Semaglutide
## Why Cigna May Deny Semaglutide for Quantity Limits
A quantity-limit denial means the amount of semaglutide dispensed — measured by dose, number of units, or day supply per fill — exceeded the quantity that Cigna's formulary or medical policy permits within a given time period. Quantity limits are a standard utilization-management tool applied to many medications, and they do not mean the drug itself is denied. They mean the specific quantity requested was above the plan's default allowance.
This type of denial most commonly arises when a prescriber writes for a supply or titration schedule that requires more units than the plan's standard quantity limit, or when a dispensing pharmacy fills a quantity that the plan has not pre-authorized.
## Why This Denial Is Appealable
Quantity limits are not clinically individualized — they are population-level defaults. If your prescriber has documented a clinical reason why you require a quantity above the standard limit (for example, a specific titration schedule, a clinically necessary supply duration, or a documented clinical characteristic that justifies the quantity), that clinical rationale is a valid basis for a quantity-limit exception appeal.
## Your Federal Appeal Rights
- Quantity-limit exception: Before or alongside a formal appeal, ask your prescriber to submit a quantity-limit exception request with clinical documentation justifying the prescribed amount.
- Internal appeal: Under ERISA §503 (employer plans) or applicable state law, you are entitled to a full-and-fair internal review. File within the deadline on your denial notice.
- External review: Under ACA §2719, if the internal appeal is denied, an independent review organization (IRO) may review whether the quantity limit as applied to your specific situation is clinically appropriate. The external-review window is generally approximately four months from the final internal denial.
- Expedited review: Available if delay would seriously jeopardize your health.
## Documentation to Gather
1. Prescription and dispensing records: Confirm the exact quantity prescribed and dispensed, the days' supply, and how it compares to Cigna's published quantity limit for semaglutide. 2. Titration or dosing rationale: A written explanation from your prescriber of why the prescribed quantity is clinically appropriate for your specific situation, referencing the FDA-approved prescribing information for semaglutide's recommended use. 3. FDA prescribing label: The approved labeling describes the recommended titration and use schedule; if your prescription aligns with label guidance, document that alignment. 4. Clinical necessity for extended supply: If a larger supply is requested for travel, adherence, or other documented clinical reasons, your prescriber should attest to that in a signed letter. 5. Prior fill history: Pharmacy records showing your history of fills, any prior-approved quantities, and your adherence record.
## Criteria-Mapping Structure
Obtain Cigna's current quantity-limit specification for semaglutide (typically listed in the formulary or the pharmacy benefit document). Address each element:
| Quantity Limit Element (from Cigna policy) | Your Clinical Justification | |--------------------------------------------|-----------------------------| | Maximum units per fill | [Prescribed quantity and clinical rationale for the amount] | | Maximum days' supply per fill | [Prescribed days' supply and prescriber justification] | | Frequency of fills allowed | [Fill history and prescriber attestation of ongoing need] | | Clinical basis for exceeding standard limit | [Prescriber letter citing FDA label and individualized clinical factors] |
Quantity-limit exceptions are routinely granted when a prescriber submits a clear, signed clinical rationale. Attach the FDA-approved prescribing information and any relevant clinical documentation to give the appeal reviewer the full picture.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →